Pathologic endpoints as surrogates for survival endpoints in neoadjuvant immunotherapy clinical trials for non-small cell lung cancer

被引：0
|
作者：
Cameron, Robert B.
Hines, Jacobi B.
Esposito, Alessandra
Bestvina, Christine
Garassino, Marina C.
Torri, Valter
Thawani, Rajat
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-3638
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3638
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer
    Mandrekar, Sumithra J.
    Qi, Yingwei
    Hillman, Shauna L.
    Ziegler, Katie L. Allen
    Reuter, Nicholas F.
    Rowland, Kendrith M., Jr.
    Kuross, Steven A.
    Marks, Randolph S.
    Schild, Steven. E.
    Adjei, Alex A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (01) : 3 - 9
  • [2] Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?
    Clarke, Jeffrey M.
    Wang, Xiaofei
    Ready, Neal E.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (06) : 804 - 808
  • [3] Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer-Clinical Trials Experience
    Chmielewska, Izabela
    Stencel, Katarzyna
    Kalinka, Ewa
    Ramlau, Rodryg
    Krawczyk, Pawel
    CANCERS, 2021, 13 (20)
  • [4] Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer
    Guo, Hanfei
    Li, Wenqian
    Qian, Lei
    Cui, Jiuwei
    CHINESE JOURNAL OF CANCER RESEARCH, 2021, 33 (02) : 203 - 215
  • [5] Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer
    Hanfei Guo
    Wenqian Li
    Lei Qian
    Jiuwei Cui
    ChineseJournalofCancerResearch, 2021, 33 (02) : 203 - 215
  • [6] Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer
    Sanber, Khaled
    Rosner, Samuel
    Forde, Patrick M.
    Marrone, Kristen A.
    BIODRUGS, 2023, 37 (06) : 775 - 791
  • [7] Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer
    Khaled Sanber
    Samuel Rosner
    Patrick M. Forde
    Kristen A. Marrone
    BioDrugs, 2023, 37 : 775 - 791
  • [8] Efficacy, innovativeness, clinical trials, endpoints, and price of drugs with FDA approval for non-small cell lung cancer (NSCLC)
    Michaeli, C. T.
    Michaeli, J. C.
    Desai, A.
    Albers, S.
    Michaeli, D. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S845 - S845
  • [9] Clinical Benefits as Endpoints in Advanced Non-Small Cell Lung Cancer Treated with Integrative Medicine
    薛冬
    李萍萍
    Chinese Journal of Integrative Medicine , 2011, (03) : 228 - 231
  • [10] Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine
    Dong Xue
    Ping-ping Li
    Chinese Journal of Integrative Medicine, 2011, 17 : 228 - 231
12345